PTCHFOTCPharmaceutical PreparationsFiscal year ends December 31Also trades as PRTCY
PureTech Health plc
Financials through fiscal 2024, year ended Dec 31, 2024Last filing: 20-F on Apr 29, 2026
$1.48+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- 7.0
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2017 to 2024
Operating margin
-2818.9%−1438.2 pts over 5 years
Net margin
1108.3%−3186.0 pts over 5 years
Growth rates
Compound annual growth to fiscal 2024
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +45.0% | -34.8% | -13.2% | – | |
| Net income | – | – | -33.8% | – | |
| EPS, diluted | – | – | -32.0% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2019 | FY2024 | Trend |
|---|---|---|---|---|
| Return on equity | – | – | 12.2% | |
| Return on assets | – | – | 8.3% | |
| Current ratio | – | 1.21 | 9.33 | |
| Debt to equity | – | 0.00 | – | |
| Net debt to EBITDA | – | 1.03× | – | |
| Interest coverage | – | -52.6× | -78.6× | |
| Capex to revenue | – | 123.8% | 0.2% | |
| Diluted shares | – | – | 256M |
Where the cash went
Fiscal 2020 to 2024, five years combined
PureTech Health generated $709.18M from operations and spent $13.00M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$709.18M
Used
$13.00M
Capital expenditure$13.00M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin1108.3%
×Asset turnover0.01×
×Equity multiplier1.48×
=Return on equity, FY202412.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2024 | 1108.3% | 0.01× | 1.48× | 12.2% |
| FY2023 | -1972.9% | 0.00× | 1.39× | -13.1% |
| FY2022 | -322.4% | 0.02× | 1.45× | -8.9% |
| FY2021 | -348.3% | 0.02× | 1.53× | -9.6% |
| FY2020 | 50.9% | 0.01× | 1.44× | 0.9% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2024 against fiscal 2023
5of 7 tests passed in fiscal 2024. Some tests lack the figures they need.
- ProfitableNet income above zero$53.51M
- Cash generatingOperating cash flow above zero-$134.37M
- Return on assets improvedROA up on the prior year-9.3% → 7.7%
- Earnings backed by cashOperating cash flow above net income-$134.37M vs $53.51M
- Less leverageLong-term debt to assets fell0.0% → –
- Better liquidityCurrent ratio rose6.76 → 9.33
- No dilutionShare count did not rise276M → 256M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.00 → 0.01